Subclinical Primary Aldosteronism in Diabetes At-Risk for Kidney Disease
Brigham and Women's Hospital
125 participants
May 15, 2024
INTERVENTIONAL
Conditions
Summary
The aim of this protocol is to assess the presence and severity of primary aldosteronism pathophysiology in patients with type 2 diabetes who have, or are at-risk for developing, chronic kidney disease.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Oral sodium suppression test (\~2 grams of supplemental sodium for 3 days)
Saline suppression test (2 liters of saline)
Captopril suppression test (50mg of captopril)
1mg of dexamethasone
250mcg of cosyntropin
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06190158